Table 2.
Treatment Outcomes after 12 Weeks of MIRI (n = 16).
| Outcomes | Values |
|---|---|
| Perianal disease activity | |
| Closure of external fistula openings, n (%) | 5 (31.3) |
| Disappearance of discharge, n (%) | 5 (31.3) |
| Seton removal by surgeon, n (%) | 4 (25) |
| Spontaneous seton drop-off, n (%) | 1 (6.3) |
| No change, n (%) | 4 (25) |
| PDAI, median (IQR) | 2 (0.8-3.0) |
| Van Assche Index score, median (IQR) | 5 (3.3-7.0) |
| Overall disease activity | |
| Clinical response, % | 68.8 |
| Clinical remission, % | 50 |
| Clinical response (remission) in bio-naive patients, % | 85.7 (42.9) |
| Clinical response (remission) in bio-experienced patients, % | 55.6 (55.6) |
| CDAI, median (IQR) | 90 (51.0-156.8) |
| Adverse events | |
| Perianal | 0 |
| Systemic | 0 |
bio-experienced: previously treated with biologic therapy; bio-naive: previously untreated with biologic therapy; CDAI: Crohn’s Disease Activity Index; IQR: interquartile range; MIRI: mirikizumab; PDAI: Perianal Disease Activity Index.